Medical
Stay up-to-date on the latest medical cannabis research, news, and information with Business of Cannabis. Learn about new treatments, laws, and more.
Medical · page 8
- Medical Cannabis
Five Years, 74 Patients: Ireland Moves Forward With Review of Its Failing Medical Cannabis Programme
The Irish government has appointed a public health academic to chair a formal review of its now five-year-old Medical Cannabis Access Programme (MCAP) following months of parliamentary pressure.
- Opinion
Is the ‘Commercial Scale’ of Medical Cannabis in the UK Inappropriate?
As the UK’s medical cannabis industry continues to come under fierce scrutiny from the country’s mainstream media, James Duckenfield, CEO of UK-based cannabis cultivator Glass Pharms, argues that the focus should be on ensuring compliance with the existing regulatory framework rather than sensationalising a prescribing rate that remains a small fraction of demonstrable clinical need.
- Medical Cannabis
Oliver’s Law: The Campaign That Could Reshape UK Cannabis Prescribing
Written by Ben Stevens & Sarah Sinclair A new campaign is calling for urgent regulatory changes to how medical cannabis is prescribed to patients in the UK, following what is believed to be the first time a coroner has found that a prescription for cannabis contributed to a death in the country.
- Industry Trends
New Report: UK and Germany Medical Cannabis Markets Both Double in 2025
The UK and Germany’s medical cannabis markets both more than doubled in size throughout 2025, once again cementing the countries as the engine behind European market growth.
- Cultivation
New Zealand’s Medical Cannabis Market Growth Slows as Major Operator Calls in Administrators
New Zealand’s medical cannabis market grew a further 25% in 2025, according to the latest official figures, seeing the country cement its position as one of the lesser-discussed but most exciting markets on the planet.
- Clinical Research
Beyond the Abstract: What the Landmark Lancet Psychiatry Cannabinoid Review Shows
A major new systematic review has concluded that the available evidence rarely justifies the routine prescribing of cannabinoids for mental health conditions and substance use disorders.
- Industry Trends
Germany’s Medical Cannabis Product Range Quadruples as Prices Fall 30%
Business of Cannabis is excited to announce the launch of German Cannabis Intel: Insights & Market Data, the inaugural report in our new quarterly series in partnership with Grünhorn.
- Industry Trends
Deals, Courts and Coalition Splits: Germany’s Cannabis Market Braces for Change
It’s now five months since the German Federal Cabinet adopted draft amendments to its pivotal Medizinal-Cannabisgesetzes (MedCanG) bill, and its finalisation is expected in the coming weeks.
- Industry Trends
Is the German Cannabis Boom Slowing Down, or Simply Normalising?
Germany’s cannabis imports, according to the latest figures from BfArM, nearly tripled in size in 2025, cementing it beyond any doubt as the engine behind Europe’s medical cannabis boom.
- Clinical Research
Rescheduling Will Reprice Medical IP, Not Retail Footprints
US cannabis rescheduling is unlikely to trigger a land grab.
- Clinical Research
The Cannabis Mental Health Evidence Gap: Association vs. Causation
In our latest Beyond the Abstract, we dive into cannabis use and its impact on mental health, a controversial and understudied field, but one of vital importance for both patient safety and potential relief for millions.
- Patient Access
Patient Protect Launches to Support UK Medical Cannabis Patients Facing Discrimination
A new UK-wide service supporting medical cannabis patients who face discrimination has launched, as the private sector continues to fill gaps left by the absence of systematic government support.
